Abstract. Dysregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling has been found in several types of human cancer, including hepatocellular carcinoma (HCC). NVP-BEZ235 is a novel, orally bioavailable dual PI3K/mTOR inhibitor that has exhibited promising activity against HCC in preclinical models. Autophagy is a cellular lysosomal degradation pathway essential for the regulation of cell survival and death to maintain homeostasis. This process is negatively regulated by mTOR signaling and often counteracts the efficacy of certain cancer therapeutic agents. In this study, we explored the role of autophagy in apoptosis induced by NVP-BEZ235 in two HCC cell lines, Hep3B and PLC/PRF/5, and identified the mechanism of combinatorial treatment. NVP-BEZ235 was effective in inhibiting the growth of the two HCC cell lines possibly though induction of apoptosis. NVP-BEZ235 also potently increased the expression of LC3-II and decreased the expression of p62, indicating induction of autophagy. When NVP-BEZ235 was used in combination with Atg5 siRNA or the autophagy inhibitor 3-methyladenine (3-MA), enhancement of the inhibitory effects on the growth of HCC cells was detected. In addition, enhanced induction of apoptosis was observed in cells exposed to the combination of NVP-BEZ235 and Atg5 siRNA or 3-MA. Thus, induction of autophagy by NVP-BEZ235 may be a survival mechanism that counteracts its anticancer effects. Based on these data, we suggest a strategy to enhance the anticancer efficacy of BEZ235 by blockade of autophagy. Thus, our study provides a rationale for the clinical development of combinations of NVP-BEZ235 and autophagy inhibitors for the treatment of HCC and other malignancies.
Introduction
Human hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, and is the third leading cause of cancer-related mortality. The incidence and mortality of HCC is inhomogenous in undeveloped and developed countries, and the majority of HCC occurs in Asia and Africa. However, its incidence has increased rapidly in the past two decades in Western Europe (1, 2) . Despite the magnitude of the disease, existing treatments are of limited efficacy. Less than 30% of the patients are suitable for curative treatment, and the recurrence is a frequent issue following tumor ablation (3) . Accordingly, new novel therapeutic approaches for HCC are urgently required.
Among the molecular mechanisms of HCC, several signaling pathways play a vital role in hepatocarcinogenesis (4) , and the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is aberrantly activated in HCC. The PI3K/AKT/mTOR signaling pathway has been the focus of research in recent years due to its potential role in cancer (5, 6) . The PI3K/AKT/mTOR signaling pathway acts as a convergence for numerous upstream signals and stimulates the activity of a multitude of downstream effectors, thereby mediating cellular survival, growth (5) . Therefore, it is not surprising that aberrant and deregulation activation of this signaling is a common molecular event in several types of malignancy (6) . These insights have resulted in the development of novel therapies targeting constituents of this pathway (single or multiple PI3K/mTOR inhibitors) and currently several inhibitors are in clinical trials (7) (8) (9) . Therefore, targeting the PI3K/AKT/mTOR signaling has become the novel therapeutic approach for human HCC treatment (9) .
Autophagy is a cellular lysosomal degradation pathway that is essential for regulation of cell survival and death to maintain cellular homeostasis (10, 11) . One of the key regulators of autophagy is mTOR, which is the major inhibitory signal that shuts off autophagy in the presence of growth factors and abundant nutrients (11) . Accordingly, inhibition of mTOR signaling (e.g., by the mTOR inhibitor rapamycin) induces autophagy (12) . Autophagy can be either a pro-survival or death mechanism depending on the circumstances (10,11), thereby generating a variable impact on the outcome of cancer therapy. In the present study, we investigated whether inhibition of autophagy would enhance the apoptosis of HCC cells.
We focused on the role of NVP-BEZ235, the effective PI3K/mTOR dual inhibitor on cancer therapy (13) (14) (15) on the induction of apoptosis in human HCC cell lines and explored the impact of autophagy induction on its anticancer activity against HCC. We also examined if combination of autophagy inhibitors with NVP-BEZ235 could enhance the apoptosis of HCC cells.
Materials and methods

Materials.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 3-methyladenine (3-MA) were purchased from Sigma. Atg5 siRNA plasmid was purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA (sc-29918). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco. The antibodies anti-caspase-3, anti-cleaved caspase-3, anti-PARP, anti-LC3, anti-Atg5, anti-AKT, anti-p-AKT, anti-p70S6K, anti-p-p70S6K and anti-p62 were purchased from Santa Cruz Biotechnology, Inc. NVP-BEZ235 was purchased from LC Laboratories.
Cell culture. The human Hep3B and PLC/PRF/5 cells were cultured in DMEM with 10% FBS, under standard culture conditions (37˚C and 5% CO 2 ).
Cell viability assays. Hep3B and PLC/PRF/5 cells were cultured in 96-well plates at a density of 1x10 4 cells/well in 100 µl of complete medium. Each group was repeated in nine separate wells. MTT reagent [12 µl, 5 mg/ml in phosphatebuffered saline (PBS)] was added to each well for 4-6 h. Following treatment, each well was dissolved in 150 µl DMSO.
Absorbance was recorded at a wavelength of 490 nm.
Western blot analysis. Hep3B and PLC/PRF/5 cells were washed with cold PBS and then 300 µl radioimmunoprecipitation (RIPA) buffer [50 mM Tris-HCl (pH 6.8), 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 0.1 mM Na 3 VO 4 , 1 mM sodium fluoride (NaF), 1% Triton X-100, 1% NP-40, 1 mM dithiothreitol, and 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A] were added to each group. Cell lysates were then shaken in a cold room (4˚C) for 30 min and centrifuged at 14,000 x g for 10 min. Protein concentrations in the supernatants were detected using the BCA protein assay. For western blot analysis, 50 µg proteins were separated by 12% (w/v) SDS-polyacrylamide gel electrophoresis. After running gels, proteins were transferred onto PVDF membranes and were then blocked with 5% (w/v) skim milk in buffer [10 mM Tris-HCl (pH 7.6), 100 mM NaCl, and 0.1% (v/v) Tween-20] for 2 h at room temperature (25˚C); the primary antibodies were added overnight on the shaker in a cold room. Then, PVDF membranes were incubated with secondary antibodies (Sigma) for 1 h at room temperature. The semi-quantitation of proteins was surveyed with a Tanon GIS gel imager system. Atg5 siRNA transfection. Prior to transfection, 50% Hep3B and PLC/PRF/5 cells were grown in each dish. These cells were transfected with 50 nmol/l of siRNA using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Cells were harvested for western blotting at 24-48 h post transfection.
Mitochondrial membrane potential (MMP) analysis.
To detect the change of MMP, we used the JC-1 staining through flow cytometry. The assay was performed according to the manufacturer's instructions (Invitrogen). Briefly, Hep3B and PLC/PRF/5 cells were trypsinized, washed with PBS twice, and resuspended in PBS at a concentration of 1-1.5x10
6 cells/ml. Hep3B and PLC/PRF/5 cells were then stained with 3 µl of JC-1 (1 mg/ml) and incubated in the dark at 37˚C for 1 h. The JC-1 positive cells were subsequently detected by a FACSCalibur flow cytometer.
Statistical analysis. The data were analyzed by t-test. P<0.05 was considered to represent a statistically significant difference. Data are representative of three independent experiments performed in triplicate.
Results
NVP-BEZ235 (NVP) inhibits growth and the PI3K/mTOR pathway of the HCC cell lines Hep3B and PLC/PRF/5.
Overexpression of PI3K/AKT/mTOR signaling has been reported in several types of cancer, including HCC (5, 9) . Targeting the PI3K/AKT/mTOR signal pathway may be the novel therapeutic approach for HCC. NVP-BEZ235 is a novel, orally bioavailable dual PI3K/mTOR inhibitor that has exhibited promising activity in preclinical models (13, 14) . First, we used MTT to detect the effect of NVP on the two HCC cell lines, Hep3B and PLC/PRF/5. NVP decreased the cell viability of the two cell lines in a dose-dependent manner ( Fig. 1A and B) . We also detected the expression of PI3K/ mTOR pathway proteins in the two cell lines treated with NVP. NVP downregulated the expression of p-AKT and p-p70S6K ( Fig. 1C and D) .
NVP induces apoptosis in Hep3B and PLC/PRF/5 cells.
Based on the above results, we further detected the apoptosisrelated proteins in Hep3B and PLC/PRF/5 treated with NVP. We detected the apoptotic relative proteins caspase-3 and PARP. NVP increased the expression of cleaved caspase-3 and cleaved PARP in Hep3B ( Fig. 2A and B) . Similar results can be seen in another HCC cell line, PLC/PRF/5 ( Fig. 2C and D) . We next measured the MMP in Hep3B and PLC/PRF/5 cells. NVP clearly induced the loss of the MMP in Hep3B and PLC/ PRF/5 cells (Fig. 2E and F) . These results indicate that NVP induces apoptosis in Hep3B and PLC/PRF/5 cells, possibly through the mitochondrial apoptotic pathway. (Fig. 3) .
Inhibition of autophagy by Atg5 siRNA enhances apoptosis induced by NVP in Hep3B and PLC/PRF/5 cells.
As shown in the results above, NVP induces apoptosis and autophagy in HCC cell lines. Autophagy is always considered a protection process when cells are under low nutrition. However, the role of autophagy in apoptosis induced by chemicals is uncertain. We first used the Atg5 siRNA plasmid to explore the role of autophagy in apoptosis induced by NVP. Atg5 siRNA inhibited the expression of Atg5 and the increase of LC3-II induced by NVP in Hep3B cells ( Fig. 4A and B) . Inhibition of autophagy by Atg5 siRNA intensified the growth inhibition of Hep3B cells induced by NVP (Fig. 4C) . Meanwhile, Atg5 siRNA further increased the apoptotic relative proteins cleaved caspase-3 and cleaved PARP induced by NVP in Hep3B cells ( Fig. 4D and E) . Atg5 siRNA also increased the loss of MMP in Hep3B cells induced by NVP (Fig. 5F ). Similar results were found in the other HCC cell line, PLC/PRF/5 (Fig. 5) . (Fig. 7) . These results indicate that autophagy plays a key role in apoptosis induced by NVP. Combination of NVP and autophagy inhibition may be a novel strategy for the treatment of HCC. 
Inhibition of autophagy by autophagy inhibitor 3-MA enhances apoptosis induced by NVP in
Discussion
HCC is a fatal cancer for men and women and is caused by complicated risk factors (16) . Due to frequent de novo and acquired resistance of HCC to chemotherapy, the effective options for therapy of HCC are limited (17, 18) . Consequently, there is a strong interest in identifying novel molecular targets for therapy of HCC. Taking into account the role of PI3K/AKT/mTOR signaling in HCC cellular survival, negating apoptosis (19) would indicate that a marked proapoptotic response to the inhibition of this signaling pathway may be expected. However, as previously found (20), apoptosis is not necessarily the primary response to PI3K/AKT/mTOR inhibition, particularly in cancer cells where marked apoptosis suppression may be the consequence of multiple genetic alterations. The current study suggests that the PI3K/AKT/mTOR inhibitors induce productive autophagy in cancer cells (21, 22) . Jung et al (23) reported that mTOR is a master regulator of autophagy through the phosphorylation of its downstream gene ULK. Thus, it is not surprising that mTOR blockade would lead to autophagy induction.
Autophagy induced by the blockade of the PI3K/AKT/ mTOR pathway has been identified in several studies as a mechanism of cell death, whereas other articles have provided data showing the role of this process in therapeutic resistance. Recent examples of the former include the finding that PI3K/ AKT/mTOR pathway inhibition increases radiosensitivity by augmenting autophagic response (24) , and that combining the dual PI3K/mTOR inhibitor NVP-BEZ235 with the mTORC1 inhibitor temsirolimus leads to cell death secondary to massive autophagic response (25) . On the contrary, autophagy blockade has been indicated as enhancing the proapoptotic effects of PI3K/mTOR inhibitors in preclinical cancer models (21, 22) .
Apoptosis and autophagy are significantly involved in cancer. Both apoptosis and autophagy play important roles in the development, cellular homeostasis and, particularly, in the oncogenesis of mammals. The mechanisms of apoptosis and autophagy are different and involve fundamentally distinct sets of regulatory and executioner molecules (26) (27) (28) . The crosstalk between apoptosis and autophagy is therefore complex, sometimes even contradictory, in nature, yet it is critical to the overall fate of the cell (29) . In some cellular settings, autophagy serves as a cell survival pathway to suppress apoptosis (30) . On the other hand, autophagy could lead to cell death, either in collaboration with apoptosis or as a back-up mechanism when apoptosis is defective (29) . Recent studies have shown that autophagy may play an important role in the regulation of cancer development and progression. Whether autophagy represents a mechanism for resisting apoptosis or a mechanism for initiating a nonapoptotic form of programmed cell death remains unclear (31) (32) (33) .
Thus, we hypothesize that inhibition of autophagy may be an effective way of improving antitumor strategies by enhancing apoptosis. In this study, we found that the combined treatment of NVP-BEZ235 and autophagy inhibition led to marked cell growth inhibition and increase of apoptosis. These results indicated that inhibition of autophagy likely impairs the proliferation mechanism of tumor cells, consequently leading to tumor cell growth inhibition. Furthermore, inhibition of autophagy increased the apoptotic marker caspase-3 activation, and thus led to the enhancement of tumor cell apoptosis. Indeed, previous studies have shown that inhibition of autophagy enhanced inhibitor-induced apoptosis (34) (35) . These findings are consistent with our hypothesis and indicate that autophagy inhibition could enhance the apoptosis of HCC cells and finally increase the growth inhibition of HCC cells. Thus, induction of autophagy by NVP-BEZ235 may be a survival mechanism that counteracts its anticancer effects. Based on these data, we suggest a strategy to enhance the anticancer efficacy of BEZ235 by blockade of autophagy.
In this study, we provided significant data indicating that inhibition of autophagy could enhance tumor cell growth inhibition and apoptosis of HCC cells induced by PI3K/mTOR inhibitor NVP-BEZ235. Thus, activation of autophagy may be involved in the resistance to apoptosis in HCC cells. Autophagy may help tumor cells mitigate metabolic stress and promote cell survival during apoptosis. In conclusion, we showed that inhibition of autophagy may be a novel way to increase the efficacy of antitumor strategies in the treatment of HCC.
